Multi-omics Integration Poised to Catapult Functional Genomics Market to $46.24 Billion by 2033 - Here’s How

02 Nov 2023

The field of precision medicine is on the cusp of a significant transformation fueled by the integration of multi-omics approaches. By delving into the wealth of data generated by diverse omics platforms such as genomics, transcriptomics, proteomics, and metabolomics, multi-omics offers a comprehensive understanding of biological systems, from the tiniest molecular components to complex phenotypic outcomes.

While genomics provides the foundation, functional genomics seeks to unravel how genetic information translates into actual phenotypic manifestations. By employing multi-omics approaches, researchers can decipher the intricate web of interactions and relationships that drive biological systems, facilitating a more profound comprehension of their functional aspects.

According to data insights from the BIS Research report, the increased application of functional genomics in targeted therapy and precision medicine is driving significant growth. It is set to boost the global functional genomics market from a valuation of $10.57 billion in 2022 to $46.24 billion by 2033, with a CAGR of 14.04%.

This article delves deep into the significance, relevance, and rise of the multi-omics approach in functional genomics and how it will advance the field of precision medicine.

Relevance of Multi-omics in Clinical Research and Applications

The following figure shows the growing popularity and relevance of the multi-omics approach for patient stratification and research applications.

In clinical research, multi-omics enables a deeper exploration of disease mechanisms, biomarker discovery, and patient stratification. Researchers can uncover complex molecular networks underlying diseases by analyzing genomic, transcriptomic, and proteomic data, identify critical genetic and molecular drivers, and develop targeted therapies.

 The multi-omics approach also facilitates the identification of specific biomarkers that can aid in early disease detection, prognosis, and treatment response prediction. This information can guide clinicians in making informed decisions and developing personalized treatment plans.

Moreover, multi-omics plays a pivotal role in patient stratification, enabling the identification of distinct disease subtypes and subpopulations with different treatment responses. This approach allows for the development of tailored interventions based on individual genetic and molecular profiles, leading to improved therapeutic outcomes.

By combining multi-omics data with clinical and lifestyle information, clinicians can comprehensively understand a patient’s unique biology, enabling precision medicine interventions that consider genetic variability, environmental factors, and lifestyle choices.

The relevance of multi-omics extends beyond research and into clinical applications. With advancements in next-generation sequencing technologies, the cost and time required for multi-omics analysis have significantly reduced, making it more accessible for clinical laboratories.

This accessibility paves the way for integrating multi-omics into routine clinical practice, enabling healthcare providers to make evidence-based decisions, select the most effective treatments, and monitor treatment response more accurately.

For instance, a significant player in the genomics industry, Illumina, played a crucial role in advancing the accessibility of multi-omics. With its next-generation sequencer, the NovaSeq X system, researchers can now generate a 125 giga base genome for a fraction of the cost compared to previous technologies.

Moreover, Illumina’s informatics and processing platform, DRAGEN, has been integrated into the NovaSeq X system, allowing for onboard analysis capabilities. This integration enables efficient analysis and the option to transfer data for further research in external databases, cloud computing software, or other DRAGEN pipelines.


Integrating multi-omics in functional genomics is poised to drive the market to unprecedented heights, reaching $46.24 billion by 2033, advancing precision medicine, disease understanding, and facilitating personalized treatments.

Interested to know more about the growing technologies in your industry vertical ? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.